Back to search
FDAFDA · Food and drugs·Recall number D-0870-2023

GLYCOPYRROLATE INJECTION, USP 0.2MG/ML, 1mL VIAL, manufactured by HF Acquisition Co. LLC, Mukilteo, WA 98275, NDC 51662-1487-3

Published June 14, 2023 · Recall initiated: June 6, 2023

Summary

FDA records drug Class III recall D-0870-2023, published June 14, 2023 and initiated June 6, 2023. Recalling firm: HF Acquisition Co LLC; Status: Terminated; Reported quantity: 9 boxes of 25 vials; Lot: Lot #: 2205095.1, Exp. Date 7/31/2024. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Label Mix-up

What to do

Voluntary: Firm initiated · Letter

Get an email if GLYCOPYRROLATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
GLYCOPYRROLATE
Manufacturer
HF Acquisition Co LLC
Distributor
Distributed in TX, AZ and CA only
Lot
Lot #: 2205095.1, Exp. Date 7/31/2024
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was GLYCOPYRROLATE INJECTION, USP 0.2MG/ML, 1mL VIAL, manufactured by HF Acquisition Co. LLC, Mukilteo, WA 98275, NDC 51662-1487-3 recalled?

Yes. FDA published recall D-0870-2023 on June 14, 2023. Reported hazard: Labeling: Label Mix-up

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: GLYCOPYRROLATE.